EANM procedure guidelines for brain PET imaging using [
Dementia
Encephalitis
Epilepsy
Glioma
Glucose
Lymphoma
Metabolism
Movement disorders
Oncology
PET
Psychiatry
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
10
09
2021
accepted:
21
10
2021
pubmed:
10
12
2021
medline:
15
3
2022
entrez:
9
12
2021
Statut:
ppublish
Résumé
The present procedural guidelines summarize the current views of the EANM Neuro-Imaging Committee (NIC). The purpose of these guidelines is to assist nuclear medicine practitioners in making recommendations, performing, interpreting, and reporting results of [
Identifiants
pubmed: 34882261
doi: 10.1007/s00259-021-05603-w
pii: 10.1007/s00259-021-05603-w
pmc: PMC8803744
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
632-651Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
Zimmer ER, Parent MJ, Souza DG, Leuzy A, Lecrux C, Kim HI, et al. [(18)F]FDG PET signal is driven by astroglial glutamate transport. Nat Neurosci. 2017;20:393–5. https://doi.org/10.1038/nn.4492 .
doi: 10.1038/nn.4492
pubmed: 28135241
pmcid: 5378483
Sweeney MD, Montagne A, Sagare AP, Nation DA, Schneider LS, Chui HC, et al. Vascular dysfunction-the disregarded partner of Alzheimer's disease. Alzheimers Dement. 2019;15:158–67. https://doi.org/10.1016/j.jalz.2018.07.222 .
doi: 10.1016/j.jalz.2018.07.222
pubmed: 30642436
pmcid: 6338083
Xiang X, Wind K, Wiedemann T, Blume T, Shi Y, Briel N, et al. Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. Sci Transl Med. 2021;13:eabe5640. https://doi.org/10.1126/scitranslmed.abe5640 .
Verger A, Lagarde S, Maillard L, Bartolomei F, Guedj E. Brain molecular imaging in pharmacoresistant focal epilepsy: current practice and perspectives. Rev Neurol. 2018;174:16–27. https://doi.org/10.1016/j.neurol.2017.05.001 .
doi: 10.1016/j.neurol.2017.05.001
pubmed: 28595975
Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Någren K, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36:2103–10. https://doi.org/10.1007/s00259-009-1264-0 .
doi: 10.1007/s00259-009-1264-0
pubmed: 19838705
Nobili F, Arbizu J, Bouwman F, Drzezga A, Agosta F, Nestor P, et al. European association of nuclear medicine and european academy of neurology recommendations for the use of brain. Eur J Neurol. 2018;25:1201–17. https://doi.org/10.1111/ene.13728 .
doi: 10.1111/ene.13728
pubmed: 29932266
Ortner MM. The use of (18)F-FDG PET in the diagnostic workup of Alzheimer's dementia. Methods Mol Biol. 1750;2018:213–9. https://doi.org/10.1007/978-1-4939-7704-8_14 .
doi: 10.1007/978-1-4939-7704-8_14
Endres D, Rauer S, Kern W, Venhoff N, Maier SJ, Runge K, et al. Psychiatric presentation of anti-NMDA receptor encephalitis. Front Neurol. 2019;10:1086. https://doi.org/10.3389/fneur.2019.01086 .
doi: 10.3389/fneur.2019.01086
pubmed: 31749755
pmcid: 6848057
Bordonne M, Chawki MB, Doyen M, Kas A, Guedj E, Tyvaert L, et al. Brain (18)F-FDG PET for the diagnosis of autoimmune encephalitis: a systematic review and a meta-analysis. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05299-y .
Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535–62. https://doi.org/10.1016/j.jalz.2018.02.018 .
doi: 10.1016/j.jalz.2018.02.018
pubmed: 29653606
pmcid: 5958625
Tan MS, Ji X, Li JQ, Xu W, Wang HF, Tan CC, et al. Longitudinal trajectories of Alzheimer's ATN biomarkers in elderly persons without dementia. Alzheimers Res Ther. 2020;12:55. https://doi.org/10.1186/s13195-020-00621-6 .
doi: 10.1186/s13195-020-00621-6
pubmed: 32393375
pmcid: 7216714
Ou YN, Xu W, Li JQ, Guo Y, Cui M, Chen KL, et al. FDG-PET as an independent biomarker for Alzheimer's biological diagnosis: a longitudinal study. Alzheimers Res Ther. 2019;11:57. https://doi.org/10.1186/s13195-019-0512-1 .
doi: 10.1186/s13195-019-0512-1
pubmed: 31253185
pmcid: 6599313
Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, Ossenkoppele R, et al. Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression. Neurology. 2015;84:508–15. https://doi.org/10.1212/WNL.0000000000001209 .
doi: 10.1212/WNL.0000000000001209
pubmed: 25568301
pmcid: 4336071
Iaccarino L, Sala A, Perani D. Initiative AsDN. Predicting long-term clinical stability in amyloid-positive subjects by FDG-PET. Ann Clin Transl Neurol. 2019;6:1113–20. https://doi.org/10.1002/acn3.782 .
doi: 10.1002/acn3.782
pubmed: 31211176
pmcid: 6562030
Chételat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, et al. Amyloid-PET and (18)F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurol. 2020;19:951–62. https://doi.org/10.1016/s1474-4422(20)30314-8 .
doi: 10.1016/s1474-4422(20)30314-8
pubmed: 33098804
Nobili F, Festari C, Altomare D, Agosta F, Orini S, Van Laere K, et al. Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders. Eur J Nucl Med Mol Imaging. 2018;45:1557–66. https://doi.org/10.1007/s00259-018-4030-3 .
doi: 10.1007/s00259-018-4030-3
pubmed: 29721650
Gjerum L, Frederiksen KS, Henriksen OM, Law I, Anderberg L, Andersen BB, et al. A visual rating scale for cingulate island sign on 18F-FDG-PET to differentiate dementia with Lewy bodies and Alzheimer's disease. J Neurol Sci. 2020;410:116645. https://doi.org/10.1016/j.jns.2019.116645 .
doi: 10.1016/j.jns.2019.116645
pubmed: 31911283
Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frölich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302–16. https://doi.org/10.1006/nimg.2002.1208 .
doi: 10.1006/nimg.2002.1208
pubmed: 12482085
Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 2008;49:390–8. https://doi.org/10.2967/jnumed.107.045385 .
doi: 10.2967/jnumed.107.045385
pubmed: 18287270
Garibotto V, Herholz K, Boccardi M, Picco A, Varrone A, Nordberg A, et al. Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:183–95. https://doi.org/10.1016/j.neurobiolaging.2016.03.033 .
doi: 10.1016/j.neurobiolaging.2016.03.033
pubmed: 28317648
Chételat G, Arbizu J, Barthel H, Garibotto V, Lammertsma AA, Law I, et al. Finding our way through the labyrinth of dementia biomarkers. Eur J Nucl Med Mol Imaging. 2021;48:2320–4. https://doi.org/10.1007/s00259-021-05301-7 .
doi: 10.1007/s00259-021-05301-7
pubmed: 33876260
Singh TD, Josephs KA, Machulda MM, Drubach DA, Apostolova LG, Lowe VJ, et al. Clinical, FDG and amyloid PET imaging in posterior cortical atrophy. J Neurol. 2015;262:1483–92. https://doi.org/10.1007/s00415-015-7732-5 .
doi: 10.1007/s00415-015-7732-5
pubmed: 25862483
pmcid: 4469094
Whitwell JL, Graff-Radford J, Singh TD, Drubach DA, Senjem ML, Spychalla AJ, et al. F-FDG PET in posterior cortical atrophy and dementia with lewy bodies. J Nucl Med. 2017;58:632–8. https://doi.org/10.2967/jnumed.116.179903 .
doi: 10.2967/jnumed.116.179903
pubmed: 27688479
pmcid: 5373504
Migliaccio R, Agosta F, Basaia S, Cividini C, Habert MO, Kas A, et al. Functional brain connectome in posterior cortical atrophy. Neuroimage Clin. 2020;25:102100. https://doi.org/10.1016/j.nicl.2019.102100 .
doi: 10.1016/j.nicl.2019.102100
pubmed: 31865020
Bouwman F, Orini S, Gandolfo F, Altomare D, Festari C, Agosta F, et al. Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia. Eur J Nucl Med Mol Imaging. 2018;45:1526–33. https://doi.org/10.1007/s00259-018-4034-z .
doi: 10.1007/s00259-018-4034-z
pubmed: 29744573
pmcid: 6061469
Salat DH, Robinson ME, Miller DR, Clark DC, McGlinchey RE. Neuroimaging of deployment-associated traumatic brain injury (TBI) with a focus on mild TBI (mTBI) since 2009. Brain Inj. 2017;31:1204–19. https://doi.org/10.1080/02699052.2017.1327672 .
doi: 10.1080/02699052.2017.1327672
pubmed: 28981347
Townley RA, Botha H, Graff-Radford J, Boeve BF, Petersen RC, Senjem ML, et al. F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus. Neuroimage Clin. 2018;18:897–902. https://doi.org/10.1016/j.nicl.2018.02.031 .
doi: 10.1016/j.nicl.2018.02.031
pubmed: 29876274
pmcid: 5987871
Videbech P. PET measurements of brain glucose metabolism and blood flow in major depressive disorder: a critical review. Acta Psychiatr Scand. 2000;101:11–20. https://doi.org/10.1034/j.1600-0447.2000.101001011.x .
doi: 10.1034/j.1600-0447.2000.101001011.x
pubmed: 10674946
Kimbrell TA, Ketter TA, George MS, Little JT, Benson BE, Willis MW, et al. Regional cerebral glucose utilization in patients with a range of severities of unipolar depression. Biol Psychiatry. 2002;51:237–52. https://doi.org/10.1016/s0006-3223(01)01216-1 .
doi: 10.1016/s0006-3223(01)01216-1
pubmed: 11839367
Kennedy SH, Evans KR, Krüger S, Mayberg HS, Meyer JH, McCann S, et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry. 2001;158:899–905. https://doi.org/10.1176/appi.ajp.158.6.899 .
doi: 10.1176/appi.ajp.158.6.899
pubmed: 11384897
Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA. Chen W, et al. positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001;286:2120–7. https://doi.org/10.1001/jama.286.17.2120 .
doi: 10.1001/jama.286.17.2120
pubmed: 11694153
Verger A, Grimaldi S, Ribeiro MJ, Frismand S, Guedj E. SPECT/PET molecular imaging for parkinsonism: a fast-developing field. Ann Neurol. 2021. https://doi.org/10.1002/ana.26187 .
Walker Z, Gandolfo F, Orini S, Garibotto V, Agosta F, Arbizu J, et al. Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia. Eur J Nucl Med Mol Imaging. 2018;45:1534–45. https://doi.org/10.1007/s00259-018-4031-2 .
doi: 10.1007/s00259-018-4031-2
pubmed: 29779045
pmcid: 6061481
Whitwell JL, Höglinger GU, Antonini A, Bordelon Y, Boxer AL, Colosimo C, et al. Radiological biomarkers for diagnosis in PSP: where are we and where do we need to be? Mov Disord. 2017;32:955–71. https://doi.org/10.1002/mds.27038 .
doi: 10.1002/mds.27038
pubmed: 28500751
pmcid: 5511762
Niethammer M, Eidelberg D. Metabolic brain networks in translational neurology: concepts and applications. Ann Neurol. 2012;72:635–47. https://doi.org/10.1002/ana.23631 .
doi: 10.1002/ana.23631
pubmed: 22941893
pmcid: 4564117
Ge J, Wu J, Peng S, Wu P, Wang J, Zhang H, et al. Reproducible network and regional topographies of abnormal glucose metabolism associated with progressive supranuclear palsy: multivariate and univariate analyses in American and Chinese patient cohorts. Hum Brain Mapp. 2018;39:2842–58. https://doi.org/10.1002/hbm.24044 .
doi: 10.1002/hbm.24044
pubmed: 29536636
pmcid: 6033655
Niethammer M, Tang CC, Feigin A, Allen PJ, Heinen L, Hellwig S, et al. A disease-specific metabolic brain network associated with corticobasal degeneration. Brain. 2014;137:3036–46. https://doi.org/10.1093/brain/awu256 .
doi: 10.1093/brain/awu256
pubmed: 25208922
pmcid: 4208467
Martí-Andrés G, van Bommel L, Meles SK, Riverol M, Valentí R, Kogan RV, et al. Multicenter validation of metabolic abnormalities related to psp according to the MDS-PSP criteria. Mov Disord. 2020;35:2009–18. https://doi.org/10.1002/mds.28217 .
doi: 10.1002/mds.28217
pubmed: 32822512
Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage. 2005;26:912–21. https://doi.org/10.1016/j.neuroimage.2005.03.012 .
doi: 10.1016/j.neuroimage.2005.03.012
pubmed: 15955501
Eckert T, Tang C, Ma Y, Brown N, Lin T, Frucht S, et al. Abnormal metabolic networks in atypical parkinsonism. Mov Disord. 2008;23:727–33. https://doi.org/10.1002/mds.21933 .
doi: 10.1002/mds.21933
pubmed: 18186116
Agosta F, Altomare D, Festari C, Orini S, Gandolfo F, Boccardi M, et al. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease. Eur J Nucl Med Mol Imaging. 2018;45:1546–56. https://doi.org/10.1007/s00259-018-4033-0 .
doi: 10.1007/s00259-018-4033-0
pubmed: 29717332
van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084–98. https://doi.org/10.1016/S0140-6736(17)31287-4 .
doi: 10.1016/S0140-6736(17)31287-4
pubmed: 28552366
Pagani M, Oberg J, De Carli F, Calvo A, Moglia C, Canosa A, et al. Metabolic spatial connectivity in amyotrophic lateral sclerosis as revealed by independent component analysis. Hum Brain Mapp. 2016;37:942–53. https://doi.org/10.1002/hbm.23078 .
doi: 10.1002/hbm.23078
pubmed: 26703938
Van Weehaeghe D, Ceccarini J, Delva A, Robberecht W, Van Damme P, Van Laere K. Prospective validation of 18F-FDG brain PET discriminant analysis methods in the diagnosis of amyotrophic lateral sclerosis. J Nucl Med. 2016;57:1238–43. https://doi.org/10.2967/jnumed.115.166272 .
doi: 10.2967/jnumed.115.166272
pubmed: 26940764
Van Laere K, Vanhee A, Verschueren J, De Coster L, Driesen A, Dupont P, et al. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol. 2014;71:553–61. https://doi.org/10.1001/jamaneurol.2014.62 .
doi: 10.1001/jamaneurol.2014.62
pubmed: 24615479
Van Weehaeghe D, Devrome M, Schramm G, De Vocht J, Deckers W, Baete K, et al. Combined brain and spinal FDG PET allows differentiation between ALS and ALS mimics. Eur J Nucl Med Mol Imaging. 2020;47:2681–90. https://doi.org/10.1007/s00259-020-04786-y .
doi: 10.1007/s00259-020-04786-y
pubmed: 32314027
Tang CC, Feigin A, Ma Y, Habeck C, Paulsen JS, Leenders KL, et al. Metabolic network as a progression biomarker of premanifest Huntington's disease. J Clin Invest. 2013;123:4076–88. https://doi.org/10.1172/JCI69411 .
doi: 10.1172/JCI69411
pubmed: 23985564
pmcid: 3754266
Feigin A, Tang C, Ma Y, Mattis P, Zgaljardic D, Guttman M, et al. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain. 2007;130:2858–67. https://doi.org/10.1093/brain/awm217 .
doi: 10.1093/brain/awm217
pubmed: 17893097
Herben-Dekker M, van Oostrom JC, Roos RA, Jurgens CK, Witjes-Ané MN, Kremer HP, et al. Striatal metabolism and psychomotor speed as predictors of motor onset in Huntington's disease. J Neurol. 2014;261:1387–97. https://doi.org/10.1007/s00415-014-7350-7 .
doi: 10.1007/s00415-014-7350-7
pubmed: 24781835
Ciarmiello A, Giovacchini G, Orobello S, Bruselli L, Elifani F, Squitieri F. 18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size. Eur J Nucl Med Mol Imaging. 2012;39:1030–6. https://doi.org/10.1007/s00259-012-2114-z .
doi: 10.1007/s00259-012-2114-z
pubmed: 22526956
Hellem MNN, Vinther-Jensen T, Anderberg L, Budtz-Jørgensen E, Hjermind LE, Larsen VA, et al. Hybrid 2-[18F] FDG PET/MRI in premanifest Huntington's disease gene-expansion carriers: the significance of partial volume correction. PLoS One. 2021;16:e0252683. https://doi.org/10.1371/journal.pone.0252683 .
doi: 10.1371/journal.pone.0252683
pubmed: 34115782
pmcid: 8195345
Peralta C, Biafore F, Depetris TS, Bastianello M. Recent advancement and clinical implications of 18FDG-PET in Parkinson's disease, atypical Parkinsonisms, and other movement disorders. Curr Neurol Neurosci Rep. 2019;19:56. https://doi.org/10.1007/s11910-019-0966-3 .
doi: 10.1007/s11910-019-0966-3
pubmed: 31256288
Guedj E, Bonini F, Gavaret M, Trébuchon A, Aubert S, Boucekine M, et al. 18FDG-PET in different subtypes of temporal lobe epilepsy: SEEG validation and predictive value. Epilepsia. 2015;56:414–21. https://doi.org/10.1111/epi.12917 .
doi: 10.1111/epi.12917
pubmed: 25708545
Lagarde S, Boucekine M, McGonigal A, Carron R, Scavarda D, Trebuchon A, et al. Relationship between PET metabolism and SEEG epileptogenicity in focal lesional epilepsy. Eur J Nucl Med Mol Imaging. 2020;47:3130–42. https://doi.org/10.1007/s00259-020-04791-1 .
doi: 10.1007/s00259-020-04791-1
pubmed: 32430581
Henry TR, Votaw JR. The role of positron emission tomography with [18F]fluorodeoxyglucose in the evaluation of the epilepsies. Neuroimaging Clin N Am. 2004;14:517–35, ix. https://doi.org/10.1016/j.nic.2004.04.011 .
doi: 10.1016/j.nic.2004.04.011
pubmed: 15324862
Van Paesschen W, Dupont P, Sunaert S, Goffin K, Van Laere K. The use of SPECT and PET in routine clinical practice in epilepsy. Curr Opin Neurol. 2007;20:194–202. https://doi.org/10.1097/WCO.0b013e328042baf6 .
doi: 10.1097/WCO.0b013e328042baf6
pubmed: 17351491
Spencer SS. The relative contributions of MRI, SPECT, and PET imaging in epilepsy. Epilepsia. 1994;35(Suppl 6):S72–89. https://doi.org/10.1111/j.1528-1157.1994.tb05990.x .
doi: 10.1111/j.1528-1157.1994.tb05990.x
pubmed: 8206016
Gok B, Jallo G, Hayeri R, Wahl R, Aygun N. The evaluation of FDG-PET imaging for epileptogenic focus localization in patients with MRI positive and MRI negative temporal lobe epilepsy. Neuroradiology. 2013;55:541–50. https://doi.org/10.1007/s00234-012-1121-x .
doi: 10.1007/s00234-012-1121-x
pubmed: 23223825
LoPinto-Khoury C, Sperling MR, Skidmore C, Nei M, Evans J, Sharan A, et al. Surgical outcome in PET-positive, MRI-negative patients with temporal lobe epilepsy. Epilepsia. 2012;53:342–8. https://doi.org/10.1111/j.1528-1167.2011.03359.x .
doi: 10.1111/j.1528-1167.2011.03359.x
pubmed: 22192050
Dupont S, Semah F, Clémenceau S, Adam C, Baulac M, Samson Y. Accurate prediction of postoperative outcome in mesial temporal lobe epilepsy: a study using positron emission tomography with 18fluorodeoxyglucose. Arch Neurol. 2000;57:1331–6. https://doi.org/10.1001/archneur.57.9.1331 .
doi: 10.1001/archneur.57.9.1331
pubmed: 10987901
Vinton AB, Carne R, Hicks RJ, Desmond PM, Kilpatrick C, Kaye AH, et al. The extent of resection of FDG-PET hypometabolism relates to outcome of temporal lobectomy. Brain. 2007;130:548–60. https://doi.org/10.1093/brain/awl232 .
doi: 10.1093/brain/awl232
pubmed: 16959818
Tomás J, Pittau F, Hammers A, Bouvard S, Picard F, Vargas MI, et al. The predictive value of hypometabolism in focal epilepsy: a prospective study in surgical candidates. Eur J Nucl Med Mol Imaging. 2019;46:1806–16. https://doi.org/10.1007/s00259-019-04356-x .
doi: 10.1007/s00259-019-04356-x
pubmed: 31144060
Akanuma N, Reed LJ, Marsden PK, Jarosz J, Adachi N, Hallett WA, et al. Hemisphere-specific episodic memory networks in the human brain: a correlation study between intracarotid amobarbital test and [(18)F]FDG-PET. J Cogn Neurosci. 2009;21:605–22. https://doi.org/10.1162/jocn.2009.21035 .
doi: 10.1162/jocn.2009.21035
pubmed: 18564051
Weintrob DL, Saling MM, Berkovic SF, Berlangieri SU, Reutens DC. Verbal memory in left temporal lobe epilepsy: evidence for task-related localization. Ann Neurol. 2002;51:442–7. https://doi.org/10.1002/ana.10133 .
doi: 10.1002/ana.10133
pubmed: 11921050
Benedetti L, Franciotta D, Zoccarato M, Beronio A, Godani M, Schirinzi E, et al. Post-therapy normalization of brain FDG-PET in Morvan's syndrome. J Neurol Sci. 2015;353:175–6. https://doi.org/10.1016/j.jns.2015.03.035 .
doi: 10.1016/j.jns.2015.03.035
pubmed: 25896288
Mauro D, Barbagallo G, Angelo DS, Sannino P, Naty S, Bruno C, et al. Role of positron emission tomography for central nervous system involvement in systemic autoimmune diseases: status and perspectives. Curr Med Chem. 2018;25:3096–104. https://doi.org/10.2174/0929867324666170523144402 .
doi: 10.2174/0929867324666170523144402
pubmed: 28545366
Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391–404. https://doi.org/10.1016/S1474-4422(15)00401-9 .
doi: 10.1016/S1474-4422(15)00401-9
pubmed: 26906964
pmcid: 5066574
Morbelli S, Arbizu J, Booij J, Chen MK, Chetelat G, Cross DJ, et al. The need of standardization and of large clinical studies in an emerging indication of [(18)F]FDG PET: the autoimmune encephalitis. Eur J Nucl Med Mol Imaging. Germany; 2017. p. 353–7.
De Leiris N, Ruel B, Vervandier J, Boucraut J, Grimaldi S, Horowitz T, et al. Decrease in the cortex/striatum metabolic ratio on [18F]-FDG PET: a biomarker of autoimmune encephalitis. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05507-9 .
Baumgartner A, Rauer S, Mader I, Meyer PT. Cerebral FDG-PET and MRI findings in autoimmune limbic encephalitis: correlation with autoantibody types. J Neurol. 2013;260:2744–53. https://doi.org/10.1007/s00415-013-7048-2 .
doi: 10.1007/s00415-013-7048-2
pubmed: 23900756
Morbelli S, Djekidel M, Hesse S, Pagani M, Barthel H. (EANM) NCotEAoNM, et al. role of (18)F-FDG-PET imaging in the diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:1009–10. https://doi.org/10.1016/S1474-4422(16)30140-5 .
doi: 10.1016/S1474-4422(16)30140-5
pubmed: 27571149
Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response assessment in neuro-oncology working group and european association for neuro-oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncology. 2016;18:1199–208. https://doi.org/10.1093/neuonc/now058 .
doi: 10.1093/neuonc/now058
pubmed: 27106405
pmcid: 4999003
Spence AM, Muzi M, Mankoff DA, O'Sullivan SF, Link JM, Lewellen TK, et al. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med. 2004;45:1653–9.
pubmed: 15471829
Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18 F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46:540–57. https://doi.org/10.1007/s00259-018-4207-9 .
Colavolpe C, Metellus P, Mancini J, Barrie M, Béquet-Boucard C, Figarella-Branger D, et al. Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas. J Neuro-Oncol. 2012;107:527–35. https://doi.org/10.1007/s11060-011-0771-6 .
doi: 10.1007/s11060-011-0771-6
Colavolpe C, Chinot O, Metellus P, Mancini J, Barrie M, Bequet-Boucard C, et al. FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. Neuro-Oncology. 2012;14:649–57. https://doi.org/10.1093/neuonc/nos012 .
doi: 10.1093/neuonc/nos012
pubmed: 22379188
pmcid: 3337300
Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med. 1998;39:778–85.
pubmed: 9591574
de Zwart PL, van Dijken BRJ, Holtman GA, Stormezand GN, Dierckx RAJO, Jan van Laar P, et al. Diagnostic accuracy of pet tracers for the differentiation of tumor progression from treatment-related changes in high-grade glioma: a systematic review and metaanalysis. J Nucl Med. 2020;61:498–504. https://doi.org/10.2967/jnumed.119.233809 .
doi: 10.2967/jnumed.119.233809
pubmed: 31541032
Hoffman JM, Waskin HA, Schifter T, Hanson MW, Gray L, Rosenfeld S, et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med. 1993;34:567–75.
pubmed: 8455072
Gupta T, Manjali JJ, Kannan S, Purandare N, Rangarajan V. Diagnostic performance of pretreatment 18F-fluorodeoxyglucose positron emission tomography with or without computed tomography in patients with primary central nervous system lymphoma: updated systematic review and diagnostic test accuracy meta-analyses. Clin Lymphoma Myeloma Leuk. 2021. https://doi.org/10.1016/j.clml.2021.03.011 .
Gupta T, Manjali JJ, Kannan S, Purandare N, Rangarajan V. Diagnostic yield of extensive systemic staging including whole-body 18f-fluoro-deoxy-glucose positron emission tomography with or without computed tomography in patients with primary central nervous system lymphoma: systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2020;20:e836–e45. https://doi.org/10.1016/j.clml.2020.06.019 .
doi: 10.1016/j.clml.2020.06.019
pubmed: 32712087
Spanaki MV, Siegel H, Kopylev L, Fazilat S, Dean A, Liow K, et al. The effect of vigabatrin (gamma-vinyl GABA) on cerebral blood flow and metabolism. Neurology. 1999;53:1518–22. https://doi.org/10.1212/wnl.53.7.1518 .
doi: 10.1212/wnl.53.7.1518
pubmed: 10534261
Liu S, Wang Y, Xu K, Ping F, Li F, Wang R, et al. Voxel-based comparison of brain glucose metabolism between patients with Cushing's disease and healthy subjects. Neuroimage Clin. 2018;17:354–8. https://doi.org/10.1016/j.nicl.2017.10.038 .
doi: 10.1016/j.nicl.2017.10.038
pubmed: 29159047
Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol. 1979;6:371–88. https://doi.org/10.1002/ana.410060502 .
doi: 10.1002/ana.410060502
pubmed: 117743
Jamar F, Buscombe J, Chiti A, Christian PE, Delbeke D, Donohoe KJ, et al. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med. 2013;54:647–58. https://doi.org/10.2967/jnumed.112.112524 .
doi: 10.2967/jnumed.112.112524
pubmed: 23359660
Clifford AH, Murphy EM, Burrell SC, Bligh MP, MacDougall RF, Heathcote JG, et al. Positron emission tomography/computerized tomography in newly diagnosed patients with giant cell arteritis who are taking glucocorticoids. J Rheumatol. 2017;44:1859–66. https://doi.org/10.3899/jrheum.170138 .
doi: 10.3899/jrheum.170138
pubmed: 28916549
Berman SM, Voytek B, Mandelkern MA, Hassid BD, Isaacson A, Monterosso J, et al. Changes in cerebral glucose metabolism during early abstinence from chronic methamphetamine abuse. Mol Psychiatry. 2008;13:897–908. https://doi.org/10.1038/sj.mp.4002107 .
doi: 10.1038/sj.mp.4002107
pubmed: 17938635
Volkow ND, Wang GJ, Shokri Kojori E, Fowler JS, Benveniste H, Tomasi D. Alcohol decreases baseline brain glucose metabolism more in heavy drinkers than controls but has no effect on stimulation-induced metabolic increases. J Neurosci. 2015;35:3248–55. https://doi.org/10.1523/JNEUROSCI.4877-14.2015 .
doi: 10.1523/JNEUROSCI.4877-14.2015
pubmed: 25698759
pmcid: 4331638
Berding G, Odin P, Brooks DJ, Nikkhah G, Matthies C, Peschel T, et al. Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET. Mov Disord. 2001;16:1014–22. https://doi.org/10.1002/mds.1212 .
doi: 10.1002/mds.1212
pubmed: 11748732
Feigin A, Fukuda M, Dhawan V, Przedborski S, Jackson-Lewis V, Mentis MJ, et al. Metabolic correlates of levodopa response in Parkinson's disease. Neurology. 2001;57:2083–8. https://doi.org/10.1212/wnl.57.11.2083 .
doi: 10.1212/wnl.57.11.2083
pubmed: 11739830
Apostolova I, Lange C, Suppa P, Spies L, Klutmann S, Adam G, et al. Impact of plasma glucose level on the pattern of brain FDG uptake and the predictive power of FDG PET in mild cognitive impairment. Eur J Nucl Med Mol Imaging. 2018;45:1417–22. https://doi.org/10.1007/s00259-018-3985-4 .
doi: 10.1007/s00259-018-3985-4
pubmed: 29502311
Sarikaya I, Sarikaya A, Sharma P. Assessing the effect of various blood glucose levels on. J Nucl Med Technol. 2019;47:313–8. https://doi.org/10.2967/jnmt.119.226969 .
doi: 10.2967/jnmt.119.226969
pubmed: 31182660
Henriksen OM, Holm S, Marner L, Law I. Effect of blood glucose and body weight on image quality in brain [18F]FDG PET imaging. Nucl Med Commun. 2020;41:1265–74. https://doi.org/10.1097/MNM.0000000000001281 .
doi: 10.1097/MNM.0000000000001281
pubmed: 32858605
Eskian M, Alavi A, Khorasanizadeh M, Viglianti BL, Jacobsson H, Barwick TD, et al. Effect of blood glucose level on standardized uptake value (SUV) in (18)F- FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements. Eur J Nucl Med Mol Imaging. 2019;46:224–37. https://doi.org/10.1007/s00259-018-4194-x .
doi: 10.1007/s00259-018-4194-x
pubmed: 30350009
Byun MS, Kim HJ, Yi D, Choi HJ, Baek H, Lee JH, et al. Region-specific association between basal blood insulin and cerebral glucose metabolism in older adults. Neuroimage Clin. 2019;22:101765. https://doi.org/10.1016/j.nicl.2019.101765 .
doi: 10.1016/j.nicl.2019.101765
pubmed: 30904824
pmcid: 6434096
Sarikaya I, Sarikaya A, Sharma P. Assessing the effect of various blood glucose levels on (18)F-FDG activity in the brain, liver, and blood pool. J Nucl Med Technol. 2019;47:313–8. https://doi.org/10.2967/jnmt.119.226969 .
doi: 10.2967/jnmt.119.226969
pubmed: 31182660
Biessels GJ, Nobili F, Teunissen CE, Simó R, Scheltens P. Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective. Lancet Neurol. 2020;19:699–710. https://doi.org/10.1016/S1474-4422(20)30139-3 .
doi: 10.1016/S1474-4422(20)30139-3
pubmed: 32445622
Viglianti BL, Wale DJ, Ma T, Johnson TD, Bohnen NI, Wong KK, et al. Effects of plasma glucose levels on regional cerebral 18F-fluorodeoxyglucose uptake: implications for dementia evaluation with brain PET imaging. Biomed Pharmacother. 2019;112:108628. https://doi.org/10.1016/j.biopha.2019.108628 .
doi: 10.1016/j.biopha.2019.108628
pubmed: 30784923
pmcid: 6714976
Cranston I, Marsden P, Matyka K, Evans M, Lomas J, Sonksen P, et al. Regional differences in cerebral blood flow and glucose utilization in diabetic man: the effect of insulin. J Cereb Blood Flow Metab. 1998;18:130–40. https://doi.org/10.1097/00004647-199802000-00002 .
doi: 10.1097/00004647-199802000-00002
pubmed: 9469154
Hasselbalch SG, Knudsen GM, Videbaek C, Pinborg LH, Schmidt JF, Holm S, et al. No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes. 1999;48:1915–21. https://doi.org/10.2337/diabetes.48.10.1915 .
doi: 10.2337/diabetes.48.10.1915
pubmed: 10512354
Bordonne M, Chawki MB, Marie PY, Zaragori T, Roch V, Grignon R, et al. High-quality brain perfusion SPECT images may be achieved with a high-speed recording using 360° CZT camera. EJNMMI Phys. 2020;7:65. https://doi.org/10.1186/s40658-020-00334-7 .
doi: 10.1186/s40658-020-00334-7
pubmed: 33146804
pmcid: 7642149
Ishizu K, Nishizawa S, Yonekura Y, Sadato N, Magata Y, Tamaki N, et al. Effects of hyperglycemia on FDG uptake in human brain and glioma. J Nucl Med. 1994;35:1104–9.
pubmed: 8014665
Hahn A, Gryglewski G, Nics L, Hienert M, Rischka L, Vraka C, et al. Quantification of task-specific glucose metabolism with constant infusion of 18F-FDG. J Nucl Med. 2016;57:1933–40. https://doi.org/10.2967/jnumed.116.176156 .
doi: 10.2967/jnumed.116.176156
pubmed: 27390156
Lassmann M, Treves ST, Group ESPDHW. Paediatric radiopharmaceutical administration: harmonization of the 2007 EANM paediatric dosage card (version 1.5.2008) and the 2010 North American consensus guidelines. Eur J Nucl Med Mol Imaging. 2014;41:1036–41. https://doi.org/10.1007/s00259-014-2731-9 .
Ruotsalainen U, Suhonen-Polvi H, Eronen E, Kinnala A, Bergman J, Haaparanta M, et al. Estimated radiation dose to the newborn in FDG-PET studies. J Nucl Med. 1996;37:387–93.
pubmed: 8667081
Wu TH, Huang YH, Lee JJ, Wang SY, Wang SC, Su CT, et al. Radiation exposure during transmission measurements: comparison between CT- and germanium-based techniques with a current PET scanner. Eur J Nucl Med Mol Imaging. 2004;31:38–43. https://doi.org/10.1007/s00259-003-1327-6 .
doi: 10.1007/s00259-003-1327-6
pubmed: 14534833
Rausch I, Ruiz A, Valverde-Pascual I, Cal-González J, Beyer T, Carrio I. Performance evaluation of the vereos PET/CT system according to the NEMA NU2-2012 standard. J Nucl Med. 2019;60:561–7. https://doi.org/10.2967/jnumed.118.215541 .
doi: 10.2967/jnumed.118.215541
pubmed: 30361382
Hsu DFC, Ilan E, Peterson WT, Uribe J, Lubberink M, Levin CS. Studies of a next-generation silicon-photomultiplier-based time-of-flight PET/CT system. J Nucl Med. 2017;58:1511–8. https://doi.org/10.2967/jnumed.117.189514 .
doi: 10.2967/jnumed.117.189514
pubmed: 28450566
van Sluis J, de Jong J, Schaar J, Noordzij W, van Snick P, Dierckx R, et al. Performance characteristics of the digital biograph vision PET/CT system. J Nucl Med. 2019;60:1031–6. https://doi.org/10.2967/jnumed.118.215418 .
doi: 10.2967/jnumed.118.215418
pubmed: 30630944
van Sluis J, Boellaard R, Somasundaram A, van Snick PH, Borra RJH, Dierckx RAJO, et al. Image quality and semiquantitative measurements on the biograph vision PET/CT system: initial experiences and comparison with the biograph mCT. J Nucl Med. 2020;61:129–35. https://doi.org/10.2967/jnumed.119.227801 .
doi: 10.2967/jnumed.119.227801
pubmed: 31253742
Chen S, Hu P, Gu Y, Yu H, Shi H. Performance characteristics of the digital uMI550 PET/CT system according to the NEMA NU2-2018 standard. EJNMMI Phys. 2020;7:43. https://doi.org/10.1186/s40658-020-00315-w .
doi: 10.1186/s40658-020-00315-w
pubmed: 32588139
pmcid: 7316913
Salvadori J, Imbert L, Perrin M, Karcher G, Lamiral Z, Marie PY, et al. Head-to-head comparison of image quality between brain. EJNMMI Res. 2019;9:61. https://doi.org/10.1186/s13550-019-0526-5 .
doi: 10.1186/s13550-019-0526-5
pubmed: 31300962
pmcid: 6626093
Rausch I, Quick HH, Cal-Gonzalez J, Sattler B, Boellaard R, Beyer T. Technical and instrumentational foundations of PET/MRI. Eur J Radiol. 2017;94:A3–A13. https://doi.org/10.1016/j.ejrad.2017.04.004 .
doi: 10.1016/j.ejrad.2017.04.004
pubmed: 28431784
Chen Y, Ying C, Binkley MM, Juttukonda MR, Flores S, Laforest R, et al. Deep learning-based T1-enhanced selection of linear attenuation coefficients (DL-TESLA) for PET/MR attenuation correction in dementia neuroimaging. Magn Reson Med. 2021;86:499–513. https://doi.org/10.1002/mrm.28689 .
doi: 10.1002/mrm.28689
pubmed: 33559218
Mecheter I, Alic L, Abbod M, Amira A, Ji J. MR image-based attenuation correction of brain pet imaging: review of literature on machine learning approaches for segmentation. J Digit Imaging. 2020;33:1224–41. https://doi.org/10.1007/s10278-020-00361-x .
doi: 10.1007/s10278-020-00361-x
pubmed: 32607906
pmcid: 7573060
Hofmann M, Pichler B, Schölkopf B, Beyer T. Towards quantitative PET/MRI: a review of MR-based attenuation correction techniques. Eur J Nucl Med Mol Imaging. 2009;36(Suppl 1):S93–104. https://doi.org/10.1007/s00259-008-1007-7 .
doi: 10.1007/s00259-008-1007-7
pubmed: 19104810
De Luca F, Bolin M, Blomqvist L, Wassberg C, Martin H, Falk DA. Validation of PET/MRI attenuation correction methodology in the study of brain tumours. BMC Med Imaging. 2020;20:126. https://doi.org/10.1186/s12880-020-00526-8 .
doi: 10.1186/s12880-020-00526-8
pubmed: 33238917
pmcid: 7690209
Ladefoged CN, Hansen AE, Henriksen OM, Bruun FJ, Eikenes L, Øen SK, et al. AI-driven attenuation correction for brain PET/MRI: clinical evaluation of a dementia cohort and importance of the training group size. Neuroimage. 2020;222:117221. https://doi.org/10.1016/j.neuroimage.2020.117221 .
doi: 10.1016/j.neuroimage.2020.117221
pubmed: 32750498
Ladefoged CN, Law I, Anazodo U, St Lawrence K, Izquierdo-Garcia D, Catana C, et al. A multi-Centre evaluation of eleven clinically feasible brain PET/MRI attenuation correction techniques using a large cohort of patients. Neuroimage. 2017;147:346–59. https://doi.org/10.1016/j.neuroimage.2016.12.010 .
doi: 10.1016/j.neuroimage.2016.12.010
pubmed: 27988322
Ladefoged CN, Andersen FL, Kjær A, Højgaard L, Law I. Resolute PET/MRI attenuation correction for O-(2-(18)F-fluoroethyl)-L-tyrosine (FET) in brain tumor patients with metal implants. Front Neurosci. 2017;11:453. https://doi.org/10.3389/fnins.2017.00453 .
doi: 10.3389/fnins.2017.00453
pubmed: 28848379
pmcid: 5554515
Chen WP, Matsunari I, Noda A, Yanase D, Yajima K, Takeda N, et al. Rapid scanning protocol for brain (18)F-FDG PET: a validation study. J Nucl Med. 2005;46:1633–41.
pubmed: 16204713
Verwer EE, Golla SSV, Kaalep A, Lubberink M, van Velden FHP, Bettinardi V, et al. Harmonisation of PET/CT contrast recovery performance for brain studies. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05201-w .
Verger A, Guedj E. The renaissance of functional F-18-FDG PET brain activation imaging. Eur J Nucl Med Mol Imaging. 2018;45:2338–41. https://doi.org/10.1007/s00259-018-4165-2 .
doi: 10.1007/s00259-018-4165-2
pubmed: 30269156
Rousseau PF, Malbos E, Verger A, Nicolas F, Lancon C, Khalfa S, et al. Increase of precuneus metabolism correlates with reduction of PTSD symptoms after EMDR therapy in military veterans: an 18F-FDG PET study during virtual reality exposure to war. Eur J Nucl Med Mol Imaging. 2019;46:1817–21. https://doi.org/10.1007/s00259-019-04360-1 .
doi: 10.1007/s00259-019-04360-1
pubmed: 31152209
Verger A, Malbos E, Reynaud E, Mallet P, Mestre D, Pergandi JM, et al. Brain metabolism and related connectivity in patients with acrophobia treated by virtual reality therapy: an (18)F-FDG PET pilot study sensitized by virtual exposure. EJNMMI Res. 2018;8:93. https://doi.org/10.1186/s13550-018-0446-9 .
doi: 10.1186/s13550-018-0446-9
pubmed: 30276498
pmcid: 6167271
Schreckenberger M, Spetzger U, Sabri O, Meyer PT, Zeggel T, Zimny M, et al. Localisation of motor areas in brain tumour patients: a comparison of preoperative [18F]FDG-PET and intraoperative cortical electrostimulation. Eur J Nucl Med. 2001;28:1394–403. https://doi.org/10.1007/s002590100582 .
doi: 10.1007/s002590100582
pubmed: 11585300
Herholz K, Pietrzyk U, Karbe H, Würker M, Wienhard K, Heiss WD. Individual metabolic anatomy of repeating words demonstrated by MRI-guided positron emission tomography. Neurosci Lett. 1994;182:47–50. https://doi.org/10.1016/0304-3940(94)90202-x .
doi: 10.1016/0304-3940(94)90202-x
pubmed: 7891885
Schelbert HR, Hoh CK, Royal HD, Brown M, Dahlbom MN, Dehdashti F, et al. Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine. J Nucl Med. 1998;39:1302–5.
pubmed: 9669415
Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med. 2000;41:661–81.
pubmed: 10768568
Lucignani G, Schmidt KC, Moresco RM, Striano G, Colombo F, Sokoloff L, et al. Measurement of regional cerebral glucose utilization with fluorine-18-FDG and PET in heterogeneous tissues: theoretical considerations and practical procedure. J Nucl Med. 1993;34:360–9.
pubmed: 8441024
Henry TR, Engel J, Mazziotta JC. Clinical evaluation of interictal fluorine-18-fluorodeoxyglucose PET in partial epilepsy. J Nucl Med. 1993;34:1892–8.
pubmed: 8229230
Graham MM, Muzi M, Spence AM, O'Sullivan F, Lewellen TK, Link JM, et al. The FDG lumped constant in normal human brain. J Nucl Med. 2002;43:1157–66.
pubmed: 12215553
Hasselbalch SG, Madsen PL, Knudsen GM, Holm S, Paulson OB. Calculation of the FDG lumped constant by simultaneous measurements of global glucose and FDG metabolism in humans. J Cereb Blood Flow Metab. 1998;18:154–60. https://doi.org/10.1097/00004647-199802000-00005 .
doi: 10.1097/00004647-199802000-00005
pubmed: 9469157
Spence AM, Muzi M, Graham MM, O'Sullivan F, Krohn KA, Link JM, et al. Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: analysis of the FDG lumped constant. J Nucl Med. 1998;39:440–8.
pubmed: 9529289
Owen OE, Morgan AP, Kemp HG, Sullivan JM, Herrera MG, Cahill GF. Brain metabolism during fasting. J Clin Invest. 1967;46:1589–95. https://doi.org/10.1172/JCI105650 .
doi: 10.1172/JCI105650
pubmed: 6061736
pmcid: 292907
Redies C, Hoffer LJ, Beil C, Marliss EB, Evans AC, Lariviere F, et al. Generalized decrease in brain glucose metabolism during fasting in humans studied by PET. Am J Phys. 1989;256:E805–10. https://doi.org/10.1152/ajpendo.1989.256.6.E805 .
doi: 10.1152/ajpendo.1989.256.6.E805
Minoshima S, Koeppe RA, Mintun MA, Berger KL, Taylor SF, Frey KA, et al. Automated detection of the intercommissural line for stereotactic localization of functional brain images. J Nucl Med. 1993;34:322–9.
pubmed: 8429356
Ohnishi T, Hoshi H, Nagamachi S, Jinnouchi S, Flores LG, Futami S, et al. High-resolution SPECT to assess hippocampal perfusion in neuropsychiatric diseases. J Nucl Med. 1995;36:1163–9.
pubmed: 7790939
Kono AK, Ishii K, Sofue K, Miyamoto N, Sakamoto S, Mori E. Fully automatic differential diagnosis system for dementia with Lewy bodies and Alzheimer's disease using FDG-PET and 3D-SSP. Eur J Nucl Med Mol Imaging. 2007;34:1490–7. https://doi.org/10.1007/s00259-007-0380-y .
doi: 10.1007/s00259-007-0380-y
pubmed: 17318545
Burdette JH, Minoshima S, Vander Borght T, Tran DD, Kuhl DE. Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections. Radiology. 1996;198:837–43. https://doi.org/10.1148/radiology.198.3.8628880 .
doi: 10.1148/radiology.198.3.8628880
pubmed: 8628880
Lehman VT, Carter RE, Claassen DO, Murphy RC, Lowe V, Petersen RC, et al. Visual assessment versus quantitative three-dimensional stereotactic surface projection fluorodeoxyglucose positron emission tomography for detection of mild cognitive impairment and Alzheimer disease. Clin Nucl Med. 2012;37:721–6. https://doi.org/10.1097/RLU.0b013e3182478d89 .
doi: 10.1097/RLU.0b013e3182478d89
pubmed: 22785496
Morbelli S, Brugnolo A, Bossert I, Buschiazzo A, Frisoni GB, Galluzzi S, et al. Visual versus semi-quantitative analysis of 18F-FDG-PET in amnestic MCI: an European Alzheimer's disease consortium (EADC) project. J Alzheimers Dis. 2015;44:815–26. https://doi.org/10.3233/JAD-142229 .
doi: 10.3233/JAD-142229
pubmed: 25362041
Perani D, Della Rosa PA, Cerami C, Gallivanone F, Fallanca F, Vanoli EG, et al. Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. Neuroimage Clin. 2014;6:445–54. https://doi.org/10.1016/j.nicl.2014.10.009 .
doi: 10.1016/j.nicl.2014.10.009
pubmed: 25389519
pmcid: 4225527
Frisoni GB, Bocchetta M, Chételat G, Rabinovici GD, de Leon MJ, Kaye J, et al. Imaging markers for Alzheimer disease: which vs how. Neurology. 2013;81:487–500. https://doi.org/10.1212/WNL.0b013e31829d86e8 .
doi: 10.1212/WNL.0b013e31829d86e8
pubmed: 23897875
pmcid: 3776529
Signorini M, Paulesu E, Friston K, Perani D, Colleluori A, Lucignani G, et al. Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [18F]FDG PET: a clinical validation of statistical parametric mapping. Neuroimage. 1999;9:63–80. https://doi.org/10.1006/nimg.1998.0381 .
doi: 10.1006/nimg.1998.0381
pubmed: 9918728
Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238–48.
pubmed: 7790950
Ishii K, Kono AK, Sasaki H, Miyamoto N, Fukuda T, Sakamoto S, et al. Fully automatic diagnostic system for early- and late-onset mild Alzheimer's disease using FDG PET and 3D-SSP. Eur J Nucl Med Mol Imaging. 2006;33:575–83. https://doi.org/10.1007/s00259-005-0015-0 .
doi: 10.1007/s00259-005-0015-0
pubmed: 16470370
Wagatsuma K, Sakata M, Ishibashi K, Hirayama A, Kawakami H, Miwa K, et al. Direct comparison of brain [(18)F]FDG images acquired by SiPM-based and PMT-based PET/CT: phantom and clinical studies. EJNMMI Phys. 2020;7:70. https://doi.org/10.1186/s40658-020-00337-4 .
doi: 10.1186/s40658-020-00337-4
pubmed: 33226451
pmcid: 7683764
Garibotto V, Trombella S, Antelmi L, Bosco P, Redolfi A, Tabouret-Viaud C, et al. A comparison of two statistical mapping tools for automated brain FDG-PET analysis in predicting conversion to Alzheimer's disease in subjects with mild cognitive impairment. Curr Alzheimer Res. 2020;17:1186–94. https://doi.org/10.2174/1567205018666210212162443 .
doi: 10.2174/1567205018666210212162443
pubmed: 33583380
Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer's disease neuroimaging initiative (ADNI): clinical characterization. Neurology. 2010;74:201–9. https://doi.org/10.1212/WNL.0b013e3181cb3e25 .
doi: 10.1212/WNL.0b013e3181cb3e25
pubmed: 20042704
pmcid: 2809036
Caminiti SP, Sala A, Presotto L, Chincarini A, Sestini S, Perani D, et al. Validation of FDG-PET datasets of normal controls for the extraction of SPM-based brain metabolism maps. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-020-05175-1 .
Thomas BA, Erlandsson K, Modat M, Thurfjell L, Vandenberghe R, Ourselin S, et al. The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2011;38:1104–19. https://doi.org/10.1007/s00259-011-1745-9 .
doi: 10.1007/s00259-011-1745-9
pubmed: 21336694
Yang J, Hu C, Guo N, Dutta J, Vaina LM, Johnson KA, et al. Partial volume correction for PET quantification and its impact on brain network in Alzheimer's disease. Sci Rep. 2017;7:13035. https://doi.org/10.1038/s41598-017-13339-7 .
doi: 10.1038/s41598-017-13339-7
pubmed: 29026139
pmcid: 5638902
López-González FJ, Silva-Rodríguez J, Paredes-Pacheco J, Niñerola-Baizán A, Efthimiou N, Martín-Martín C, et al. Intensity normalization methods in brain FDG-PET quantification. Neuroimage. 2020;222:117229. https://doi.org/10.1016/j.neuroimage.2020.117229 .
doi: 10.1016/j.neuroimage.2020.117229
pubmed: 32771619
Mortensen KN, Gjedde A, Thompson GJ, Herman P, Parent MJ, Rothman DL, et al. Impact of global mean normalization on regional glucose metabolism in the human brain. Neural Plast. 2018;2018:6120925. https://doi.org/10.1155/2018/6120925 .
doi: 10.1155/2018/6120925
pubmed: 30008742
pmcid: 6020504
Borghammer P, Jonsdottir KY, Cumming P, Ostergaard K, Vang K, Ashkanian M, et al. Normalization in PET group comparison studies--the importance of a valid reference region. Neuroimage. 2008;40:529–40. https://doi.org/10.1016/j.neuroimage.2007.12.057 .
doi: 10.1016/j.neuroimage.2007.12.057
pubmed: 18258457
Borghammer P. Perfusion and metabolism imaging studies in Parkinson's disease. Dan Med J. 2012;59:B4466.
pubmed: 22677251
Yakushev I, Landvogt C, Buchholz HG, Fellgiebel A, Hammers A, Scheurich A, et al. Choice of reference area in studies of Alzheimer's disease using positron emission tomography with fluorodeoxyglucose-F18. Psychiatry Res. 2008;164:143–53. https://doi.org/10.1016/j.pscychresns.2007.11.004 .
doi: 10.1016/j.pscychresns.2007.11.004
pubmed: 18930634
Zhang H, Wu P, Ziegler SI, Guan Y, Wang Y, Ge J, et al. Data-driven identification of intensity normalization region based on longitudinal coherency of 18 F-FDG metabolism in the healthy brain. Neuroimage. 2017;146:589–99. https://doi.org/10.1016/j.neuroimage.2016.09.031 .
doi: 10.1016/j.neuroimage.2016.09.031
pubmed: 27693611
Morbelli S, Arbizu J, Booij J, Chen MK, Chetelat G, Cross DJ, et al. The need of standardization and of large clinical studies in an emerging indication of [18 F]FDG PET: the autoimmune encephalitis. Eur J Nucl Med Mol Imaging. 2017;44:353–7. https://doi.org/10.1007/s00259-016-3589-9 .
doi: 10.1007/s00259-016-3589-9
pubmed: 27924371
Drzezga A, Arnold S, Minoshima S, Noachtar S, Szecsi J, Winkler P, et al. 18F-FDG PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis. J Nucl Med. 1999;40:737–46.
pubmed: 10319744
Busemann Sokole E, Płachcínska A, Britten A, Lyra Georgosopoulou M, Tindale W, Klett R, et al. Routine quality control recommendations for nuclear medicine instrumentation. Eur J Nucl Med Mol Imaging. 2010;37:662–71. https://doi.org/10.1007/s00259-009-1347-y .
doi: 10.1007/s00259-009-1347-y
pubmed: 20130859
Cook GJ, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med. 1999;26:1363–78. https://doi.org/10.1007/s002590050597 .
doi: 10.1007/s002590050597
pubmed: 10541839
Sala A, Caprioglio C, Santangelo R, Vanoli EG, Iannaccone S, Magnani G, et al. Brain metabolic signatures across the Alzheimer's disease spectrum. Eur J Nucl Med Mol Imaging. 2020;47:256–69. https://doi.org/10.1007/s00259-019-04559-2 .
doi: 10.1007/s00259-019-04559-2
pubmed: 31811345
McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305–13. https://doi.org/10.1016/S1474-4422(07)70057-1 .
doi: 10.1016/S1474-4422(07)70057-1
pubmed: 17362834
Morbelli S, Esposito G, Arbizu J, Barthel H, Boellaard R, Bohnen NI, et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging. 2020;47:1885–912. https://doi.org/10.1007/s00259-020-04817-8 .
Brown RK, Bohnen NI, Wong KK, Minoshima S, Frey KA. Brain PET in suspected dementia: patterns of altered FDG metabolism. Radiographics. 2014;34:684–701. https://doi.org/10.1148/rg.343135065 .
doi: 10.1148/rg.343135065
pubmed: 24819789
Nestor PJ, Balan K, Cheow HK, Fryer TD, Knibb JA, Xuereb JH, et al. Nuclear imaging can predict pathologic diagnosis in progressive nonfluent aphasia. Neurology. 2007;68:238–9. https://doi.org/10.1212/01.wnl.0000251309.54320.9f .
doi: 10.1212/01.wnl.0000251309.54320.9f
pubmed: 17224582
Nestor PJ, Altomare D, Festari C, Drzezga A, Rivolta J, Walker Z, et al. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. Eur J Nucl Med Mol Imaging. 2018;45:1509–25. https://doi.org/10.1007/s00259-018-4035-y .
doi: 10.1007/s00259-018-4035-y
pubmed: 29736698
Whitwell JL, Duffy JR, Strand EA, Machulda MM, Senjem ML, Schwarz CG, et al. Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. Brain Lang. 2015;142:45–53. https://doi.org/10.1016/j.bandl.2015.01.009 .
doi: 10.1016/j.bandl.2015.01.009
pubmed: 25658633
pmcid: 4380294
Zorzi G, Cecchin D, Busse C, Perini G, Corbetta M, Cagnin A. Changes of metabolic connectivity in dementia with Lewy bodies with visual hallucinations: a 18F-FDG PET/MR study. Brain Connect. 2021. https://doi.org/10.1089/brain.2020.0988 .
Scheltens NME, van der Weijden K, Adriaanse SM, van Assema D, Oomen PP, Krudop WA, et al. Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. Neuroimage Clin. 2018;19:625-32. https://doi.org/10.1016/j.nicl.2018.05.024 .